Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 4/20 | 0.32 |
| ▸ | FLT1 | P17948 | 3/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 5/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26984844 | 0.95 | SYK (0.31) | SYKHDAC3HDAC1HDAC6 | |
| SCHEMBL30746579 | 0.95 | SYK (0.31) | SYKHDAC3HDAC1HDAC6 | |
| SCHEMBL30746646 | 0.93 | MKNK1 (0.34) | SYKSSTR4CSF1RAAK1DHODH | |
| SCHEMBL26984989 | 0.93 | MKNK1 (0.34) | SYKSSTR4CSF1RAAK1DHODH | |
| SCHEMBL30746429 | 0.92 | FPR2 (0.37) | HDAC3HDAC1HDAC6SSTR4KDR | |
| SCHEMBL26985087 | 0.92 | FPR2 (0.37) | HDAC3HDAC1HDAC6SSTR4KDR | |
| SCHEMBL26985070 | 0.92 | NUDT1 (0.40) | SYKCSF1RKDRFLT1AAK1 | |
| SCHEMBL30746399 | 0.91 | MAP2K2 (0.33) | SYKDHODHMAP2K2MAP2K1 | |
| SCHEMBL30746634 | 0.91 | BRAF (0.34) | KDM4E | |
| SCHEMBL26984940 | 0.91 | BRAF (0.34) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4551558-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | Nested Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024010925-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010925-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK6, MAPK3, MAPK1 | SYK 1038/4885HDAC3 265/4885HDAC1 603/4885 |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | BRAF, MAP3K1, MAP3K5 | SYK 693/4885HDAC3 2213/4885HDAC1 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.